DR. JULIE A JOHNSON, PHARM.D.
Pharmacy at Archer Rd, Gainesville, FL
License number
Florida 03317131
Category
Pharmacy
Type
Pharmacotherapy
License number
Florida PS36111
Category
Pharmacy
Type
Pharmacotherapy
Address
Address
2
1600 SW Archer Rd RM PG-22, Gainesville, FL 32610
8152 Alderman Rd, Melrose, FL 32666
8152 Alderman Rd, Melrose, FL 32666
Phone
(352) 273-6007
Personal information
See more information about JULIE A JOHNSON at radaris.comName
Address
Phone
1652 Yachtsmans Ct, Fernandina, FL 32034
1637 Lady Slipper Cir, Orlando, FL 32825
1617 Sutton Pl, Fort Walton Beach, FL 32547
1629 Hampton Pl, Orange Park, FL 32003
17200 SW 296Th St, Homestead, FL 33030
Professional information
Non-Profit Organization Management Professional
Location:
Gainesville, Florida Area
Industry:
Nonprofit Organization Management
Non-Profit Organization Management Professional
Location:
Gainesville, Florida Area
Industry:
Nonprofit Organization Management
Julie A Johnson, Gainesville FL - PHARMD
Specialties:
Pharmacotherapy
Address:
1600 SW Archer Rd SUITE PG-22, Gainesville 32610
(352) 273-6007 (Phone)
(352) 273-6007 (Phone)
Languages:
English
Beta-Adrenoceptor Genetic Polymorphisms And Obesity
US Patent:
2004003, Feb 19, 2004
Filed:
Jul 10, 2003
Appl. No.:
10/617846
Inventors:
Julie Johnson - Melrose FL, US
International Classification:
C12Q001/68, A61K031/137
US Classification:
435/006000, 514/651000
Abstract:
The present invention provides a method for identifying a subject having a risk of developing obesity, coronary microvasular dysfunction, or hypertension, comprising detection of the presence of a single nucleotide polymorphism (SNP) in a nucleic acid encoding an element of at least one -adrenergic receptor from the subject. The presence of the SNP is correlated with obesity, coronary microvascular dysfunction, or hypertension, and thereby identifies the subject as having a risk of developing obesity, coronary microvascular dysfunction, of hypertension. The subject invention also provides methods of identifying patients likely to benefit from the prescription of beta blocker hypertension medications. In various embodiments, the nucleic acids detected include those genes encoding ADRB1 (AR), ADRB2 (AR), ADRB3 (AR), GNB3 (G protein 3 subunit), or GNAS1 (Gprotien alpha subunit). Methods of treating identified individuals are also provided.
Beta-Adrenoceptor Genetic Polymorphisms And Obesity
US Patent:
2002018, Dec 12, 2002
Filed:
Feb 12, 2002
Appl. No.:
10/075490
Inventors:
Julie Johnson - Melrose FL, US
International Classification:
C12Q001/68, A61K031/137
US Classification:
435/006000, 514/651000
Abstract:
The present invention provides a method for identifying a subject having a risk of developing obesity, coronary microvascular dysfunction, or hypertension, comprising detection of the presence of a single nucleotide polymorphism (SNP) in a nucleic acid encoding an element of at least one -adrenergic receptor from the subject. The presence of the SNP is correlated with obesity, coronary microvascular dysfunction, or hypertension, and thereby identifies the subject as having a risk of developing obesity, coronary microvascular dysfunction, or hypertension. The subject invention also provides methods of identifying patients likely to benefit from the prescription of beta blocker hypertension medications. In various embodiments, the nucleic acids detected include those genes encoding ADRB1 (AR), ADRB2 (AR), ADRB3 (AR), GNB3 (G protein 3 subunit), or GNAS1 (Gprotein alpha subunit). Methods of treating identified individuals are also provided.
Use Of Genetic Determinants In Cardiovascular Risk Assessment
US Patent:
2010002, Jan 28, 2010
Filed:
May 15, 2009
Appl. No.:
12/466895
Inventors:
Julie Johnson - Melrose FL, US
Amber L. Beitelshees - Gainesville FL, US
Michael Pacanowski - Gainesville FL, US
Harm Knot - Gainesville FL, US
Amber L. Beitelshees - Gainesville FL, US
Michael Pacanowski - Gainesville FL, US
Harm Knot - Gainesville FL, US
Assignee:
University of Florida Research Foundation, Inc. - Gainesville FL
International Classification:
C12Q 1/68, C40B 40/08, C07H 21/04
US Classification:
435 6, 506 17, 536 2433
Abstract:
The invention generally provides compositions and methods of using a subject's genetic information for the selection of prophylactic or therapeutic agents and treatment regimens, and related methods for assaying the risk of an adverse cardiovascular event in the patient.
B-Blocker Pharmacogenetics In Heart Failure
US Patent:
2008026, Oct 30, 2008
Filed:
Feb 17, 2006
Appl. No.:
11/816480
Inventors:
Julie Johnson - Melrose FL, US
Steven Terra - Ledyard CT, US
Steven Terra - Ledyard CT, US
Assignee:
University of Florida Research Foundation, Inc. - Gainesville FL
International Classification:
A61K 31/137, C12Q 1/68, A61P 9/00
US Classification:
514651, 435 6
Abstract:
Polymorphisms in the beta-1 adrenergic receptor that (1) affect tolerability to beta-blocker treatment or (2) influence responsiveness to beta-blocker treatment are disclosed. Additionally, methods of predicting that an individual would obtain clinical improvement in left ventricular function as a result of β-blocker therapy or identifying at least one individual that would obtain a clinical improvement in left ventricular function as a result of β-blocker therapy are provided. Methods of treating patients characterized by such polymorphisms are also illustrated.